The EPS beat and NDA submission are positive catalysts. Watch for ASCO presentation (June 2026) and potential FDA acceptance of NDA. The cash runway into 2028 removes near-term financing risk. Monitor for any regulatory updates on varegacestat and initial data from IM-1021 later in 2026.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $22.20entry
- T+1 · 6mo ago 0.00%α +0.00% · $22.20
- T+5 · 6mo ago −11.44%α −10.28% · $19.66
- T+20 · 5mo ago −17.30%α −16.68% · $18.36
- T+60 · 3mo ago +12.75%α +8.31% · $25.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA submission for varegacestat in desmoid tumors is the key catalyst, with ASCO oral presentation and EU MAA planned. Cash runway into 2028 supports pipeline execution.
Key Financial Metrics
Key Facts
- NDA submitted to FDA for varegacestat in desmoid tumors (April 2026)
- Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026
- Q1 2026 net loss $53.8M ($-0.48/share) vs consensus $-0.60, 20% beat
- Cash and equivalents $582.7M, runway into 2028
- IND clearance received for IM-1617 (solid tumor ADC) in April 2026
- Phase 1 trial of IM-3050 (FAP-targeted radiotherapy) initiated March 2026
- Collaboration revenue declined to $0 from $2.9M YoY (prior period had revenue)
Financial Impact
EPS beat of 20% vs consensus; cash burn $53.8M/quarter; $582.7M cash position
Risk Factors
- FDA regulatory risk for varegacestat NDA, no guarantee of approval
- No collaboration revenue in Q1 2026 vs $2.9M in Q1 2025
- Operating loss widening to $59.3M from $44.6M YoY
- Pre-revenue biotech, entirely dependent on pipeline success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219367 |
| Document: imnm-20260512.htm | 0001193125-26-219367 |
| Document: 0001193125-26-219367-index-headers.html | 0001193125-26-219367 |
| Document: 0001193125-26-219367-index.html | 0001193125-26-219367 |
| Document: 0001193125-26-219367.txt | 0001193125-26-219367 |
| 8-K Data (Synthetic) | 0001193125-26-219367 |
Track record
20 reports on IMNM
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers